Purchase Order 75N95021P00417
Award Date 8/12/21
Potential Completion Date 5/11/23
Potential Value $36K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization, to evaluate NNMT inhibitors in various metabolic disorder animal models. The contract, with a potential value of $114,040, requires Pharmaron to conduct 4-week dosing studies in multiple mouse and rat models to assess the effects of NNMT inhibitor compounds on food intake, body weight,...
- This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
- This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
- This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
- This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc., a global contract research organization (CRO) specializing in preclinical research services. The $10,656.00 contract is for a pharmacokinetic (PK) study in mice, with a final completion date of September 21, 2026. The work will be performed at Pharmaron's division in Louisville, Kentucky....
- This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
- This firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health within the Department of Health and Human Services, to Pharmaron, Inc. for $64,090. The contract is for Pharmaron to conduct a 14-day dose range-finding toxicity study in male and female rats to determine the maximally tolerated dose of an investigational molecule under development by NCATS. Specifically, Pharmaron will test the...
- This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation. The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. This...
- This is a $249,167.58 firm fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Gempharmatech LLC, a foreign-owned for-profit biotech company. The contract is for the development of humanized mouse models for nicotinamide N-methyltransferase (NNMT) and sulfotransferase (SULT1A1) using CRISPR knock-in technology. The contractor will conduct biochemical testing of inhibitors and...
- This federal contract award was issued by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a global contract research organization. The $87,805.00 firm fixed price contract was awarded as a delivery order under the NIH Bioanalysis Testing Services 2015-2020 master contract vehicle. Under this contract, Pharmaron conducted various drug development activities for NCATS, including...